top of page

March 2023 // Communication Synendos featured in Scrip article

Updated: May 30, 2023

The most recent ‘Scrip Asks’ instalments from the ‘What Does 2023 Hold For Biopharma’ series focuses on therapeutic area advances and includes an overview on the potential in CNS.

Our CEO/CSO Andrea Chicca is quoted:


“Following late-stage failures in neuropsychiatric and neurodegenerative diseases such as schizophrenia and Alzheimer’s a decade ago, several large pharma scaled back or exited the neuroscience field,” said Andrea Chicca, CEO and chief scientific officer of Synendos Therapeutics AG , which is developing endocannabinoid modulators for CNS disorders. “Now that is changing and we see real momentum building in neuroscience again with VC funding back to number two behind oncology”


The link to the Scrip article for subscribers is: https://bit.ly/3ZgbjG8


Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord

September 2022 // Company & Communication

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, c

bottom of page